Fabry Cardiomyopathy
Definition
Fabry cardiomyopathy is the cardiac manifestation of Anderson–Fabry disease (AFD), resulting from progressive Gb3 glycolipid accumulation in cardiomyocytes, intramyocardial vessels, endocardium, valvular fibroblasts, and conduction tissue. It presents as a hypertrophic cardiomyopathy genocopy — morphologically indistinguishable from sarcomeric HCM without multimodality imaging — and is responsible for the majority of morbidity and mortality in AFD patients of both sexes. (sources/fabry-ehj-2024, rating: high)
Key Concepts
Pathophysiology
- Primary mechanism: Lysosomal Gb3 storage in cardiac cells disrupts cellular processes, impairs contractile and relaxation properties (sarcomeric myofilament dysfunction, myofibrillolysis), and impairs lysosomal functions (endocytosis, autophagy). (sources/fabry-ehj-2024, rating: high)
- Mitochondrial dysfunction: Lysosomal impairment leads to mitochondrial dysfunction; dysregulation of mitochondrial microRNAs involved in energetic metabolism, biogenesis, oxidative damage, and apoptosis. Resulting energetic deficit activates hypertrophic signalling. (sources/fabry-ehj-2024, rating: high)
- Inflammation: Gb3 activates invariant NKT cells and TLR-4 pathways; defective autophagy through inflammasome activators and ROS → chronic myocardial inflammation → interstitial and replacement fibrosis. (sources/fabry-ehj-2024, rating: high)
- Electrophysiology: Enhanced Na⁺/Ca²⁺ channel function in AFD cardiomyocytes → shorter, higher action potentials → ECG abnormalities (short PQ, P-wave duration) and arrhythmia substrate. (sources/fabry-ehj-2024, rating: high)
- Sequence of damage: Gb3 storage → reduced native CMR T1 (>45% myocytes already vacuolated when T1 falls) → myocyte hypertrophy → wall thickening → interstitial fibrosis → LGE → systolic dysfunction. Storage begins early in life; tissue damage precedes imaging detection. (sources/fabry-ehj-2024, rating: high)
CMR Staging (4 Stages)
- Stage 1 (pre-LVH): Reduced native T1 only; no LVH, no LGE. Earliest CMR sign of Gb3 storage; ECG changes may be present.
- Stage 2 (LVH + inflammation): LVH + T2 elevation (basal inferolateral, reflecting myocardial oedema/inflammation) ± early inferolateral LGE.
- Stage 3 (extensive fibrosis): Extensive LGE + inferolateral wall thinning; T1 pseudo-normalises in LGE regions (fibrosis replaces storage). Symptomatic HFpEF common.
- Stage 4 (systolic dysfunction): Systolic dysfunction + advanced fibrosis; HFrEF; high arrhythmic risk.
- (sources/fabry-ehj-2024, rating: high)
Diagnostic Approach — Cardiac Red Flags
ECG
- Early: Short P-wave duration, short PQ interval (<120 ms), prolonged R-wave peak time, lower 4/8 QRS spatial velocity — pre-LVH markers.
- Advanced: High voltages, ST-T depression, T-wave inversions (precordial ± inferolateral leads). Sinus bradycardia; AV block in diffuse damage.
- (sources/fabry-ehj-2024, rating: high)
Echocardiography
- Concentric biventricular hypertrophy (dominant pattern)
- Disproportionate papillary muscle hypertrophy (characteristic)
- Hyperechogenic myocardium in some cases
- Impaired GLS even without LVH (speckle tracking — detects subclinical dysfunction)
- Mild-to-moderate mitral and aortic valve thickening ± regurgitation
- LVOTO uncommon; severe valvular disease uncommon
- (sources/fabry-ehj-2024, rating: high)
Cardiac MRI
- Native T1 mapping: Reduced T1 = earliest CMR marker of Gb3 storage (Stage 1; predates LVH).
- T2 mapping: Elevation in basal inferolateral segment = inflammation/oedema (Stage 2).
- Late gadolinium enhancement (LGE): Midwall/epicardial inferolateral pattern; pseudo-normalisation of T1 in fibrotic regions.
- Extracellular volume (ECV): Remains largely normal in AFD (unlike amyloidosis and advanced HCM) — except in advanced stages with extensive interstitial fibrosis.
- CMR recommended every 2–3 years (or more frequently if rapid progression suspected).
- (sources/fabry-ehj-2024, rating: high)
Histopathology
Myocyte Vacuolisation — "Zebra Bodies"
- Hallmark histopathological finding: Gb3 deposits form "lamellated zebra bodies" — concentric lamellar inclusions in myocytes and endothelial cells visible on electron microscopy. (sources/fabry-pcvd-2025, rating: medium)
- Intracellular vacuoles reduce effective contractile mass; disrupts cellular architecture and processes.
- Gb3 deposits represent only a minimal percentage of total cardiac mass despite being histologically prominent.
Interstitial Fibrosis
- Driven by TGF-β and CTGF upregulation from Gb3-induced cellular stress → cardiac fibroblast activation → matrix synthesis > degradation.
- Extent of fibrosis correlates with severity of diastolic dysfunction and arrhythmic risk.
- Established fibrosis is largely irreversible — early treatment before fibrosis sets in is critical.
- Fibrosis is a key prognostic marker: increased LGE → worse cardiovascular event risk. (sources/fabry-pcvd-2025, rating: medium)
Biomarkers
Lyso-Gb3 (Primary Biomarker)
- Most sensitive and specific biomarker for AFD; measured by mass spectrometry.
- Correlates directly with disease severity and organ burden (cardiac and renal); remains elevated even in late-onset phenotypes.
- Useful for early diagnosis, disease monitoring, and assessing treatment response (drop expected with effective ERT/migalastat).
- Specificity caveat: Lyso-Gb3 is Fabry-specific — not a general LVH screening biomarker (LVH also caused by hypertension, aortic stenosis). (sources/fabry-pcvd-2025, rating: medium)
Established Cardiac Biomarkers
- NT-proBNP: Elevated in LVH; indicates HF risk; useful early detection tool. (sources/fabry-pcvd-2025, rating: medium)
- hs-cTn: Elevated levels indicate myocardial injury; correlate with cardiac impairment severity; guide treatment. (sources/fabry-pcvd-2025, rating: medium)
Emerging Biomarkers
- microRNAs: non-invasive markers of cardiovascular pathology in AFD; mechanistically involved.
- miR-17: Regulates Warburg effect in skeletal muscle of Fabry patients — links to fatigue mechanism (from the Santulli group). (sources/fabry-pcvd-2025, rating: medium)
Clinical Profiles
Heart Failure
- HFpEF is the dominant phenotype — 40% of AFD patients meet ESC HF criteria; 91% of these are HFpEF.
- Subclinical diastolic dysfunction may precede LVH.
- SGLT2 inhibitors (dapagliflozin/empagliflozin) should be considered — Class I evidence for HFpEF; potential additional renal benefit in AFD nephropathy. (sources/fabry-ehj-2024, rating: high; concepts/HFpEF)
Coronary Microvascular Disease and MINOCA
- Structural/functional changes of intramural vessels → myocardial ischaemia despite normal epicardial coronaries.
- Angina with normal coronary arteries (ANOCA) and MINOCA are common, early manifestations — particularly in females; often leads to unnecessary coronary angiography.
- Coronary microvascular dysfunction associated with worse prognosis.
- (sources/fabry-ehj-2024, rating: high)
Arrhythmias
- Ventricular arrhythmias: Palpitations in ~30%; Gb3 + fibrosis = VT substrate; syncope and SCD risk in advanced disease.
- Atrial fibrillation: Atrial Gb3 infiltration and remodelling; haemodynamic deterioration; increased stroke risk.
- Conduction system: Sinus bradycardia, chronotropic incompetence (common, worsen HF); AV block (less common, advanced disease).
- (sources/fabry-ehj-2024, rating: high)
Management of Cardiac Complications
General Principles
- Foundational (disease-specific) therapy must be accompanied by guideline-based cardiological management. (sources/fabry-ehj-2024, rating: high)
- Cardiological follow-up: ECG + echo + Holter annually; CMR every 2–3 years; hs-troponin + NT-proBNP for monitoring.
Heart Failure
- Treat HFpEF per current ESC/AHA guidelines.
- SGLT2 inhibitors — should be considered (Class I ESC for HFpEF; also benefit AFD nephropathy). (sources/fabry-ehj-2024, rating: high)
- Cardiac myosin inhibitors (mavacamten) — must NOT be used in AFD (approved only for sarcomeric obstructive HCM). (sources/fabry-ehj-2024, rating: high)
- Septal reduction therapies (myectomy, alcohol ablation) for LVOTO with persistent symptoms.
Atrial Fibrillation
- Follow AF guidelines; catheter ablation experience sparse in AFD; outcomes may be suboptimal due to atrial remodelling.
- Prefer DOACs over warfarin to minimise cerebral microbleed risk and warfarin nephropathy. (sources/fabry-ehj-2024, rating: high)
SCD Prevention
- HCM Risk-SCD calculator must NOT be used in AFD — explicitly not validated for this population. (sources/fabry-ehj-2024, rating: high)
- ICD in primary prevention should be considered in patients with:
- Massive LVH AND extensive CMR scarring, PLUS at least one of:
- Arrhythmic/unexplained syncope
- NSVT on Holter monitoring
- Indication for pacing
- Antiarrhythmic drugs limited by coexisting LVH, HF, and renal dysfunction.
- Amiodarone is contraindicated — interferes with lysosomal function, worsens enzymatic deficiency, may impair ERT and migalastat efficacy. (sources/fabry-ehj-2024, rating: high)
Anticoagulation
- Prefer DOACs over vitamin K antagonists for thromboembolic prevention. (sources/fabry-ehj-2024, rating: high)
Contradictions / Open Questions
- CMR T1 vs. histology lag: Reduced T1 was considered the earliest CMR marker, but correlation studies showed >45% of myocytes are already vacuolated when T1 begins to fall — implying the imaging threshold is later than previously assumed. The 'pre-T1' stage of storage is not currently detectable by non-invasive means. (sources/fabry-ehj-2024, rating: high)
- ERT efficacy on cardiac endpoints in non-classic AFD: Long-term cardiac efficacy data for ERT in late-onset AFD are weak; most evidence is from mixed classic/late-onset populations. The degree to which ERT modifies cardiac outcomes in late-onset patients remains unclear. (sources/fabry-ehj-2024, rating: high)
- Migalastat in vitro vs. in vivo amenability: Discrepancy between laboratory amenability assay and real-world clinical response; some 'amenable' variants may not be treatable with migalastat. (sources/fabry-ehj-2024, rating: high)
- SCD risk stratification: No validated AFD-specific SCD risk model exists. HCM Risk-SCD is explicitly excluded. ICD indications are based on expert consensus rather than prospective RCT data. (sources/fabry-ehj-2024, rating: high)
- ERT paradox — may worsen cardiac fibrosis: A meta-analysis of 11 cardiac MRI studies showed ERT augmented LGE (increased myocardial fibrosis). Histological data from patients on ERT ≥18 months demonstrated cardiomyocyte disarray, severe vacuolisation, cell death, and fibrosis. Heart disease remains the most common cause of death in Fabry disease despite widespread ERT use. Whether this reflects disease progression despite ERT, direct ERT-related harm, or selection of sicker patients for imaging is unresolved — but it challenges the assumption of reliable cardiac protection from ERT. (sources/fabry-pcvd-2025, rating: medium)
- T1 mapping — directional inconsistency across sources: The EHJ 2024 review correctly states reduced native T1 = early Gb3 storage marker (reflecting lipid-laden intracellular vacuoles with short T1 relaxation). The PCVD 2025 review states "elevated T1 values correlate with Gb3" — this appears to be an internal error in the paper, likely conflating native T1 (reduced in early storage) with post-contrast T1 or ECV measurements (elevated in fibrosis). Clinically, reduced native T1 = early Fabry storage is the established and validated finding. (sources/fabry-ehj-2024, rating: high; sources/fabry-pcvd-2025, rating: medium — error in latter)
Connections
- Related to entities/Anderson-Fabry-Disease
- Related to concepts/HFpEF — HFpEF dominant phenotype in AFD
- Related to concepts/Late-Gadolinium-Enhancement — inferolateral midwall/epicardial LGE
- Related to concepts/Phenotypic-Approach-to-Cardiomyopathy — AFD as HCM genocopy
- Related to concepts/LVOTO — uncommon; myosin inhibitors contraindicated
- Related to concepts/HCM-Risk-SCD — not applicable
- Related to concepts/AAV-Gene-Delivery — gene therapy under investigation
- Related to entities/Amiodarone — contraindicated
- Related to sources/fabry-ehj-2024
- Related to sources/fabry-pcvd-2025